Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson's Disease Patients with Motor Complications
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 23, 2025
A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 23, 2025
Evaluating the prevalence of metabolic dysfunction associated steatotic liver disease (MASLD) during pregnancy and its influence on pregnancy outcomes and postpartum maternal health
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 29, 2025
Venetoclax In Combination with ASTX727, an All-Oral TherapY for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY- MDS/MPN): a Randomized, Phase 2 trial
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 22, 2025
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 2, 2025
A Multicentre, Prospective, Open-Label, Uncontrolled Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Atenativ in Patients with Congenital Antithrombin Deficiency Undergoing Surgery Or Delivery
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 2, 2025
Use of Blood, Tumor Tissue, and Tumor Infiltrating Lymphocyte Biospecimens for Immune Cell Profiling and Research
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 2, 2025
A Phase 2 Crossover Study Of On-Demand Prep Formulations Comparing Rectal And Oral Tenofovir-Based Prep Evaluating Extended Safety, Acceptability, And Pharmacokinetics/Pharmacodynamics
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 13, 2025
A Phase 3b, open label, randomized, standard-of-care control arm, multicenter, superiority study evaluating the efficacy, safety and tolerability of injectable CAB LA + RPV LA in viremic participants living with HIV-1 (CROWN)
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 13, 2025
A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants with Chronic HDV Infection (ECLIPSE 1)
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 19, 2025